To determine whether the administration of NWL283 resulted in functional recovery at later times post-stroke, mice were treated daily with the low-dose 21 mg/kg NWL283 until PSD8 and assessed on the foot-fault task and gait analysis at baseline, PSD3, PSD8 and PSD21 (Figure 4C). The gene discussed is PSD3; the disease is stroke disorder.